Pediatric Vacciness Market Likely To Reach A Valuation Of Around USD 60.4 Billion By 2025:Key Participant GlaxoSmithKline plc, Pfizer, Inc.

San Francisco, 31 December 2018,  Pediatric Vaccines Market Analysis By Type (Monovalent, Multivalent), By Technology (Live Attenuated, Inactivated, Subunit, Toxoid, Conjugate), By Application (Infectious Diseases, Cancer, Allergy), By Region, And Segment Forecasts, 2018 – 2025

The global pediatric vaccines market is expected to reach USD 60.4 billion by 2025 at an 11.7% CAGR, according to a new report by Grand View Research, Inc. Advancements in development of vaccines and new product launches are some of the major drivers of the market. 

Increase in investments by companies to capture a larger market share is anticipated to propel growth. Some of the factors attributed to increase in investment are high growth prospects in the emerging market, immunization schedule mandated by doctors for children, and awareness programs led by UNICEF, WHO, and other healthcare organizations. Furthermore, increase in number of government initiatives for raising awareness about immunization is expected to boost the market for pediatric vaccines.

Advancements in development of novel adjuvants and therapeutic vaccines are expected to drive growth during the forecast period. Ongoing research in novel molecules targeted at specific mechanisms of action in the body is aimed at providing immunity against fatal diseases such as cancer and Zika virus disease. For instance, in June 2016, Inovio Pharmaceuticals, Inc. announced the initiation of phase I clinical trial for their Zika DNA vaccine named GLS-5700.

Access Full Research Report On Pediatric Vaccines Market  Analysis:
www.grandviewresearch.com/industry-analysis/pediatric-vaccine-market

Further key findings from the report suggest:

·         The global pediatric vaccines market was estimated at USD 22.4 billion in 2016 and is expected to grow with a CAGR of 11.7% from 2017 to 2025

·         By type, monovalent emerged as the largest segment due to factors such as high usage and increase in initiatives for R&D activities supported by various governments

·         Conjugate vaccines formed the dominant technology segment in terms of revenue in 2016. Higher adoption of these vaccines and increase in prevalence of infectious diseases contribute to its lead in the market for pediatric vaccines

·         By application, the cancer segment is expected to witness the fastest growth with a CAGR of 12.6% owing to increasing prevalence of cancer and rising need for immunization against the disease

·         North America held the largest revenue share in 2016. Its dominance in the market for pediatric vaccines is owing to factors such as local presence of major players in the industry and extensive R&D activities

·         The Asia Pacific region is anticipated to witness lucrative growth over the next decade due to increase in prevalence of infectious diseases and a large target population

·         Key players such as GlaxoSmithKline plc; Pfizer, Inc.; SANOFI; and AstraZeneca dominated the global market for pediatric vaccines in 2016.

Browse More Reports Of This Category By Grand View Research At:   www.grandviewresearch.com/industry/pharmaceuticals

Grand View Research has segmented the global pediatric vaccines market on the basis of type, technology, application, and region:

Type Outlook (Market Revenue in USD Billion, 2014 - 2025)

·         Monovalent

·         Multivalent

Technology Outlook (Market Revenue in USD Billion, 2014 - 2025)

·         Live Attenuated

·         Inactivated

·         Subunit

·         Toxoid

·         Conjugate

·         Others

Application Outlook (Market Revenue in USD Billion, 2014 - 2025)

·         Infectious disease

·         Cancer

·         Allergy

Regional Outlook (Revenue, USD Billion, 2014 - 2025)

·         North America

o    U.S.

o    Canada

·         Europe

o    Germany

o    U.K.

·         Asia Pacific

o    China

o    Japan

o    India

·         Latin America

o    Brazil

o    Mexico

·         Middle East & Africa

o    South Africa

Access Full Press Release of this Report:

www.grandviewresearch.com/press-release/global-pediatric-vaccine-market

About Grand View Research

Grand View Research, Inc. is a U.S. based market research and consulting company, registered in the State of California and headquartered in San Francisco. The company provides syndicated research reports, customized research reports, and consulting services. To help clients make informed business decisions, we offer market intelligence studies ensuring relevant and fact-based research across a range of industries, from technology to chemicals, materials and healthcare.

For more information: www.grandviewresearch.com/

PCOS Treatment Market Expected To Trigger A Revenue Increase To USD 5.1 Billion By 2025:Key Participant AstraZeneca, Bayer AG

San Francisco, 24 December 2018,  Polycystic Ovarian Syndrome (PCOS) Treatment Market Analysis By Drugs (Oral Contraceptives, Antiandrogen, Insulin-Sensitizing Agents, Antidepressants, Anti-obesity), By Surgery, And Segment Forecasts, 2018 - 2025

The global polycystic ovarian syndrome treatment market is expected to reach USD 5.1 billion by 2025, according to a new report by Grand View Research, Inc. According to the Centers of Disease Control & Prevention (CDC), Polycystic Ovary Syndrome (PCOS) is the most common cause of female infertility. Approximately 6% to 12% women of reproductive age suffer from PCOS in the U. S. Moreover, progression of this condition can lead to metabolic abnormalities, which may result in development of type 2 diabetes, if the syndrome is not treated on time. The severity of the disorder increases the risk of developing uterine and endometrial cancers in patients. Thus, early diagnosis and effective treatment are significant for successful recovery. 

Presently, no specific drug is commercially available for this condition. Thus, treating symptoms is the prime aim of the treatment regimen. Owing to the various symptoms associated with this syndrome, a range of drug class/combinations is used in the treatment. Therefore, market leaders are focusing on developing a specific drug/treatment to cure the root cause of this disease. AstraZeneca is one of the leaders involved in developing such a drug.

Access Full Research Report On Polycystic Ovarian Syndrome (PCOS) Treatment Market  Analysis:

www.grandviewresearch.com/industry-analysis/polycystic-ovarian-syndrome-pcos-treatment-market

Further Key Findings from the Study Suggest:

·         Constantly rising prevalence of PCOS is primarily driving the growth of this market across the globe

·         Initiatives undertaken by government bodies and market players to create awareness about benefits of early diagnosis and commercially available treatment for PCOS among women is boosting the market

·         Treatment of PCOS mainly includes lifestyle modification through balanced diet, exercise, and drugs such as oral contraceptives, antiandrogens, insulin-sensitizing agents, anti-obesity agents, and antidepressants

·         Surgical procedures such as ovarian wedge resection and laparoscopic ovarian drilling are preferred when patients do not respond to drug therapy

·         Insulin-sensitizing agents segment is dominating the market since these drugs are widely used for treatment of insulin resistance to prevent diabetes, which is a risk associated with PCOS

·         Oral Contraceptive Pills (OCPs) segment is expected to grow at the fastest rate followed by antiandrogen agents that are used for treating symptomatic conditions such as hirsutism and acne

·         North America is dominating the market followed by Europe. High awareness and availability of advanced healthcare facilities are factors responsible for the dominant share held by this region

·         Asia Pacific is expected to be the fastest growing region over the forecast period.Increasing government initiatives for raising awareness about symptoms & diagnosis of PCOS and available treatment are increasing the number of women being diagnosed with this syndrome in the region

·         China is one of the most lucrative markets with tremendous growth opportunities for global as well as local players owing to presence of a large pool of obese female population, which is at high risk of PCOS

·         Key players in the market include AstraZeneca, Bayer AG, Merck KGaA, Abbott, Sanofi, Pfizer, Inc., Bristol-Myer Squibb Company, and Novartis AG. The market also includes other emerging players such as Teva Pharmaceutical Industries Limited and Ferring Pharmaceuticals, Inc., which are expected to grow significantly in the near future.

Browse More Reports Of This Category By Grand View Research At:   www.grandviewresearch.com/industry/pharmaceuticals

Grand View Research has segmented the PCOS treatment market on the basis of drug class, surgery type, and region:

Drug Class Outlook (Revenue, USD Billion; 2014 - 2025)

·         Oral Contraceptives

·         Antiandrogens

·         Insulin Sensitizing Agent

·         Antidepressant

·         Anti-obesity

Surgery Outlook (Revenue, USD Billion; 2014 - 2025)

·         Ovarian Wedge Resection

·         Laparoscopic Ovarian Drilling

Regional Outlook (Revenue, USD Billion; 2014 - 2025)

·         North America

o    U.S.

o    Canada

·         Europe

o    Germany

o    UK

·         Asia Pacific

o    China

o    Japan

·         Latin America

o    Mexico

o    Brazil

·         MEA

o    South Africa

Access Full Press Release of this Report:
www.grandviewresearch.com/press-release/global-polycystic-ovarian-syndrome-pcos-treatment-market

About Grand View Research

Grand View Research, Inc. is a U.S. based market research and consulting company, registered in the State of California and headquartered in San Francisco. The company provides syndicated research reports, customized research reports, and consulting services. To help clients make informed business decisions, we offer market intelligence studies ensuring relevant and fact-based research across a range of industries, from technology to chemicals, materials and healthcare.

For more information: www.grandviewresearch.com/

SLE Market Worth USD 3.08 Billion By 2025 | Key Industry Players Pfizer, Novartis

The global Systemic Lupus Erythematosus Market size is expected to reach USD 3.08 billion by 2025, according to a new report by Grand View Research, Inc., exhibiting a CAGR of 7.0% during the forecast period.Introduction of new biological therapies, which will add to treatment alternatives and medication costs, in the development pipeline is estimated to fuel revenue generation of the market. Certain new promising drugs that are currently in Phase III trials are anticipated to augment the market as these drugs may target the lupus nephritis patient subset with few effective alternatives and significant unmet needs to be met. This factor is likely to have a strong impact on the market as nearly 50.0% of SLE patients suffer with lupus nephritis.

Use of approved biologic, Benlysta, through clinical studies, has revealed drastic improvements and substantial decrease in consumption of anti-inflammatory glucocorticoids in moderate SLE cases. GSK’s current initiatives center on further increasing opportunities for Benlysta. The company is conducting indication expansion clinical trials, combination therapy studies with rituximab, and new product development, to widen opportunities for its therapy. In this direction, recent launch of Benlysta’s subcutaneous formulation in several countries is expected to boost the SLE market over the forecast period.

Full Research Report On Systemic Lupus Erythematosus Market Analysis:
www.grandviewresearch.com/industry-analysis/systemic-lupus-erythematosus-sle-market

Further key findings from the study suggest:

·         North America was the major contributor for the SLE market revenue in 2017 and is anticipated to rise at a CAGR of 8.1% during the forecast period. This is due to availability of reimbursement and better healthcare infrastructure and accessibility to biologics.

·         Europe was ranked as the second largest regional market in the SLE market in 2017 and is expected to register a CAGR of 5.5% over the forecast period

·         Immunosuppressants held the largest share in the market in 2017 due to their low cost and high accessibility, whereas the biologics segment is projected to post the highest CAGR during the same period

·         In 2017, the oral segment held the dominant share of over 54.0% in the market, followed by the intravenous segment that requires trained medical personnel for administration. Over the forecast years, the latter is poised to expand at a CAGR of 10.4%

·         Key players in this space include GlaxoSmithKline, Roche, Pfizer, Novartis, Bayer, and Sanofi. By 2025, other companies such as ImmuPharma, Aurinia Pharmaceuticals, and Astra Zeneca are anticipated to enter the SLE market.

Browse More Reports Of This Category By Grand View Research At: https://www.grandviewresearch.com/industry/pharmaceuticals

Grand View Research has segmented the global systemic lupus erythematosus market by drug class, route of administration, and region:

Systemic Lupus Erythematosus Drug Classes Outlook (Revenue, USD Million, 2014 - 2025)

·         NSAIDs

·         Corticosteroids

·         Antimalarials

·         Immunosuppressants

·         Biologics

Systemic Lupus Erythematosus Route of Administration Outlook (Revenue, USD Million, 2014 - 2025)

·         Oral

·         Intravenous

·         Subcutaneous

Systemic Lupus Erythematosus Regional Outlook (Revenue, USD Million, 2014 - 2025)

·         North America

o    U.S.

o    Canada

·         Europe

o    U.K.

o    Germany

o    France

o    Italy

o    Spain

o    Greece

o    Sweden

o    Norway

o    Poland

o    RoE

·         Asia Pacific

o    Japan

o    China

o    Hong Kong

o    Taiwan

o    South Korea

o    New Zealand

o    Australia

o    India

o    Malaysia

o    Singapore

·         Latin America

o    Brazil

o    Mexico

o    Argentina

·         MEA

o    Turkey

o    Saudi Arabia

o    Kuwait

o    Israel

o    South Africa

Access Full Press Release of this Report: 

www.grandviewresearch.com/press-release/global-systemic-lupus-erythematosus-sle-market

About Grand View Research

Grand View Research, Inc. is a U.S. based market research and consulting company, registered in the State of California and headquartered in San Francisco. The company provides syndicated research reports, customized research reports, and consulting services. To help clients make informed business decisions, we offer market intelligence studies ensuring relevant and fact-based research across a range of industries, from technology to chemicals, materials and healthcare.

For more information: www.grandviewresearch.com